Rain Therapeutics Inc. (RAIN) Reports In-Line Q3 EPS

Rain Therapeutics Inc. (NASDAQ: RAIN) reported Q3 EPS of ($0.68), in-line with the analyst estimate of ($0.68).

For earnings history and earnings-related data on Rain Therapeutics Inc. (RAIN) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55
• ClearSign Technologies (CLIR) Tops Q2 EPS by 8c